CVRx located in Maple Grove, MN, has developed an implantable device for the treatment of hypertension, or high blood pressure, in patients who cannot control their blood pressure with medications and lifestyle modifications. The company received FDA approval for an investigational device exemption (IDE) to begin a pivotal clinical trial to evaluate the safety and effectiveness of its RheosTM Baroreflex Hypertension TherapyTM System. The device has had early clinical success in European and U.S. feasibility clinical trials, and has demonstrated it can significantly reduce blood pressure in patients with drug- resistant hypertension. CVRx is private company and its senior management and technical teams have many years of experience commercializing implantable medical devices.